A Phase 2 interventional study of IMC-1121B and Moxifloxacin in Cancer and Solid Tumor, sponsored by Eli Lilly and Company. Completed at 7 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2015-06-10.
Sponsored by Eli Lilly and Company · Phase 2 and Interventional
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to determine if Ramucirumab (IMC-1121B) causes prolongation of the QT/QTc interval in participants with advanced cancer.
The primary purpose of this study is to determine if treatment with ramucirumab causes prolongation of the QTc/QT interval in participants with advanced cancer, to assess the safety and tolerability of ramucirumab therapy, and to evaluate the pharmacokinetic (PK) characteristics of ramucirumab
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 68 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active-control participants (first 16 participants) will receive one dose of moxifloxacin orally 7 days before the first treatment with ramucirumab. All participants will undergo triplicate electrocardiogram (ECG) tests (consisting of three individual ECGs performed consecutively within a period of 4 minutes) and vital signs at various times over the trial period. For Cycle 1, all participants will also receive 2 infusions of diphenhydramine before ramucirumab therapy (the first infusion is 1 day before therapy and the second infusion is 15 minutes before therapy). For Cycles 2, 3, and 4, all participants will receive diphenhydramine 15 minutes before ramucirumab therapy. For Cycle 5 and beyond, diphenhydramine infusions before ramucirumab therapy are at the investigator's discretion. Ramucirumab \[10 milligrams per kilogram (mg/kg)\] intravenously over 60 minutes, once every 3 weeks for minimum of 9 weeks without a break in between.
Biological: IMC-1121B · Drug: Moxifloxacin · Drug: Diphenhydramine
IMC-1121B (Ramucirumab) 10 mg/kg intravenously (IV) over 60 minutes, once every 3 weeks for minimum of 9 weeks.
Also known as: Ramucirumab, LY3009806
Administered orally
Administered IV
Change From Baseline to Cycle 3 in QT/Corrected QT (QTc) Interval Prolongation in Participants
All electrocardiogram (ECG) tests were performed in triplicate prior to ramucirumab treatment. QT is the interval between the Q and T waves and QTc is the QT corrected for heart rate using Fridericia's formula: QTc = QT/RR\^0.33 where RR is the interval between 2 R waves. Each participant's mean QT/QTc value was calculated for each ECG test during Cycle 3 and compared to his/her mean pretreatment QT/QTc value. The greatest change from baseline during Cycle 3 was reported. QTc prolongation is defined as a QTc exceeding 10 milliseconds (msec) with a lower 90% confidence interval (CI) exceeding 5 msec at any postdose time points per the International Conference on Harmonization (ICH) E14 guidelines for non-thorough QT studies (ICH 2005; ICH 2008). Least squares (LS) mean was calculated using a linear mixed model for repeated measures (MMRM) and adjusted for serum concentration.
Time frame: Baseline, Cycle 3 (1 cycle=21 days)
Number of Participants With Drug-Related Adverse Events (AEs)
Data presented are the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade 3 or higher TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered to be related to ramucirumab. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events section.
Time frame: Baseline up to data cut off (approximately 105.6 weeks)
Maximum Concentration (Cmax) During Cycle 1
Maximum observed concentration of IMC-1121B (ramucirumab) in serum during Cycle 1 (1 cycle=21 days).
Time frame: Cycle 1 [2.25 hours (h), 3.25 h, 4.25 h, 72 h, 168 h, 336 h postdose]
Maximum Concentration (Cmax) During Cycle 1, Day 4
Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 3 for Cmax during Cycle 1.
Time frame: Approximately Week 1 (Cycle 1, Day 4)
Maximum Concentration (Cmax) During Cycle 1, Day 8
Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 3 for Cmax during Cycle 1.
Time frame: Approximately Week 2 (Cycle 1, Day 8)
Maximum Concentration (Cmax) During Cycle 1, Day 15
Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 3 for Cmax during Cycle 1.
Time frame: Approximately Week 3 (Cycle 1, Day 15)
Maximum Concentration (Cmax) During Cycle 2
Cmax was not calculated due to the sparse pharmacokinetic sampling employed on Cycle 2, Day 1.
Time frame: Cycle 2 (predose and 1.25 hours postdose)
Maximum Concentration (Cmax) During Cycle 3
The maximum observed serum concentration of IMC-1121B (ramucirumab) at steady state (Cmax,ss) during Cycle 3 (1 cycle=21 days).
Time frame: Cycle 3 [predose and 1.25 hours (h), 2.25 h, 3.25 h, 4.25 h, 72 h, 168 h, 336 h, and 504 h postdose]
Area Under Concentration (AUC) During Cycle 1
The area under the concentration versus time curve from time 0 to infinity \[AUC(0-inf)\] is reported during Cycle 1 (1 cycle=21 days).
Time frame: Cycle 1 [2.25 hours (h), 3.25 h, 4.25 h, 72 h, 168 h, 336 h postdose]
Area Under Concentration (AUC) During Cycle 1, Day 4
AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).
Time frame: Approximately Week 1 (Cycle 1, Day 4)
Area Under Concentration (AUC) During Cycle 1, Day 8
AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).
Time frame: Approximately Week 2 (Cycle 1, Day 8)
Area Under Concentration (AUC) During Cycle 1, Day 15
AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).
Time frame: Approximately Week 3 (Cycle 1, Day 15)
Area Under Concentration (AUC) During Cycle 2, Day 1
AUC was not calculated due to the sparse pharmacokinetic sampling employed on Cycle 2, Day 1.
Time frame: Approximately Week 1 (Cycle 2, Day 1)
Area Under Concentration (AUC) During Cycle 3
The area under the concentration versus time curve over the dosing interval at steady state \[AUC(tau,ss)\] is reported during Cycle 3 (1 cycle=21 days).
Time frame: Cycle 3 [predose and 1.25 hours (h), 2.25 h, 3.25 h, 4.25 h, 72 h, 168 h, 336 h, and 504 h postdose]
| Milestone | IMC-1121B (Ramucirumab) |
|---|---|
| Started | 68 |
| Received at least 1 dose of study drug | 66 |
| Completed | 60 |
| Not completed | 8 |
| Withdrew: Lost to follow-up | 2 |
| Withdrew: Withdrawal by subject | 3 |
| Withdrew: Physician decision | 2 |
| Withdrew: Adverse event | 1 |
All electrocardiogram (ECG) tests were performed in triplicate prior to ramucirumab treatment. QT is the interval between the Q and T waves and QTc is the QT corrected for heart rate using Fridericia's formula: QTc = QT/RR\^0.33 where RR is the interval between 2 R waves. Each participant's mean QT/QTc value was calculated for each ECG test during Cycle 3 and compared to his/her mean pretreatment QT/QTc value. The greatest change from baseline during Cycle 3 was reported. QTc prolongation is defined as a QTc exceeding 10 milliseconds (msec) with a lower 90% confidence interval (CI) exceeding 5 msec at any postdose time points per the International Conference on Harmonization (ICH) E14 guidelines for non-thorough QT studies (ICH 2005; ICH 2008). Least squares (LS) mean was calculated using a linear mixed model for repeated measures (MMRM) and adjusted for serum concentration.
| milliseconds (msec) | IMC-1121B (Ramucirumab) |
|---|---|
| Change From Baseline to Cycle 3 in QT/Corrected QT (QTc) Interval Prolongation in Participants | 3.9132 (1.2880 to 6.5385) |
Data presented are the number of participants who experienced treatment-emergent adverse events (TEAEs), serious adverse events (SAEs), Grade 3 or higher TEAEs, or adverse events (AEs) leading to discontinuation of treatment that were considered to be related to ramucirumab. A summary of SAEs and other non-serious AEs, regardless of causality, is located in the Reported Adverse Events section.
| participants | IMC-1121B (Ramucirumab) |
|---|---|
| Related TEAE | 42 |
| Related SAE | 11 |
| Related Grade 3 or higher TEAE | 14 |
| Related AE leading to discontinuation | 6 |
Maximum observed concentration of IMC-1121B (ramucirumab) in serum during Cycle 1 (1 cycle=21 days).
| micrograms per milliliter (mcg/mL) | IMC-1121B (Ramucirumab) |
|---|---|
| Maximum Concentration (Cmax) During Cycle 1 | 485 ± 43 |
Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 3 for Cmax during Cycle 1.
No measurements were reported for this outcome.
Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 3 for Cmax during Cycle 1.
No measurements were reported for this outcome.
Cmax was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 3 for Cmax during Cycle 1.
No measurements were reported for this outcome.
Cmax was not calculated due to the sparse pharmacokinetic sampling employed on Cycle 2, Day 1.
No measurements were reported for this outcome.
The maximum observed serum concentration of IMC-1121B (ramucirumab) at steady state (Cmax,ss) during Cycle 3 (1 cycle=21 days).
| micrograms per milliliter (mcg/mL) | IMC-1121B (Ramucirumab) |
|---|---|
| Maximum Concentration (Cmax) During Cycle 3 | 571 ± 41 |
The area under the concentration versus time curve from time 0 to infinity \[AUC(0-inf)\] is reported during Cycle 1 (1 cycle=21 days).
| hours*micrograms/milliliter (h*mcg/mL) | IMC-1121B (Ramucirumab) |
|---|---|
| Area Under Concentration (AUC) During Cycle 1 | 67400 ± 38 |
AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).
No measurements were reported for this outcome.
AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).
No measurements were reported for this outcome.
AUC was summarized once per cycle because participants only received 1 dose of IMC-1121B (ramucirumab) per cycle. Refer to secondary outcome measure 9 for AUC during Cycle 1 (Day 1 through Day 15).
No measurements were reported for this outcome.
AUC was not calculated due to the sparse pharmacokinetic sampling employed on Cycle 2, Day 1.
No measurements were reported for this outcome.
The area under the concentration versus time curve over the dosing interval at steady state \[AUC(tau,ss)\] is reported during Cycle 3 (1 cycle=21 days).
| hours*micrograms/milliliter (h*mcg/mL) | IMC-1121B (Ramucirumab) |
|---|---|
| Area Under Concentration (AUC) During Cycle 3 | 69900 ± 41 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| IMC-1121B (Ramucirumab) | — | 32/66 (48.5%) | 61/66 (92.4%) |
| Event | IMC-1121B (Ramucirumab) |
|---|---|
| Disease progressionGeneral disorders | 6/66 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 6/66 |
| Abdominal painGastrointestinal disorders | 4/66 |
| DehydrationMetabolism and nutrition disorders | 4/66 |
| Neoplasm malignantNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 3/66 |
| NauseaGastrointestinal disorders | 2/66 |
| VomitingGastrointestinal disorders | 2/66 |
| HyponatraemiaMetabolism and nutrition disorders | 2/66 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 2/66 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 2/66 |
| Event | IMC-1121B (Ramucirumab) |
|---|---|
| Decreased appetiteMetabolism and nutrition disorders | 22/66 |
| NauseaGastrointestinal disorders | 21/66 |
| FatigueGeneral disorders | 21/66 |
| HeadacheNervous system disorders | 20/66 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 18/66 |
| Abdominal painGastrointestinal disorders | 16/66 |
| DiarrhoeaGastrointestinal disorders | 16/66 |
| VomitingGastrointestinal disorders | 16/66 |
| CoughRespiratory, thoracic and mediastinal disorders | 14/66 |
| Oedema peripheralGeneral disorders | 11/66 |
Safety population: Participants who received any quantity of ramucirumab, regardless of their eligibility for the study.
| Age, Customized(participants) | IMC-1121B (Ramucirumab) |
|---|---|
| Between 18 and 65 years | 40 |
| >=65 years | 26 |
| Sex: Female, Male(Participants) | IMC-1121B (Ramucirumab) |
|---|---|
| Female | 30 |
| Male | 36 |
| Race/Ethnicity, Customized(participants) | IMC-1121B (Ramucirumab) |
|---|---|
| White | 60 |
| Black | 5 |
| Asian | 1 |
| Region of Enrollment(participants) | IMC-1121B (Ramucirumab) |
|---|---|
| United States | 66 |
| Ethnicity(participants) | IMC-1121B (Ramucirumab) |
|---|---|
| Hispanic or Latino | 4 |
| Non-Hispanic or Latino | 62 |
The record gives a start of Nov 2009, a primary completion of Apr 2010 and a completion of May 2014. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2014, 4 years 2 months after primary completion. A results delay was requested in Jul 2010.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Ramucirumab